Compass Therapeutics (CMPX) Equity Average: 2023-2025
Historic Equity Average for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $151.4 million.
- Compass Therapeutics' Equity Average rose 6.44% to $151.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 6.44%. This contributed to the annual value of $136.9 million for FY2024, which is N/A change from last year.
- Compass Therapeutics' Equity Average amounted to $151.4 million in Q3 2025, which was up 48.82% from $101.7 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Equity Average high stood at $171.8 million for Q2 2023, and its period low was $101.7 million during Q2 2025.
- Its 3-year average for Equity Average is $144.0 million, with a median of $151.5 million in 2024.
- Over the last 5 years, Compass Therapeutics' Equity Average had its largest YoY gain of 6.44% in 2025, and its largest YoY loss of 32.88% in 2025.
- Compass Therapeutics' Equity Average (Quarterly) stood at $154.3 million in 2023, then dropped by 14.57% to $131.8 million in 2024, then rose by 6.44% to $151.4 million in 2025.
- Its Equity Average was $151.4 million in Q3 2025, compared to $101.7 million in Q2 2025 and $117.8 million in Q1 2025.